ERBB2 and ductal breast carcinoma in situ: Thorat et al. [52] reported HER2 expression (IHC 3+) in 34.4% of DCIS cases, however they did not distinguish between cases of luminal B HER2-positive and those of “pure” HER2-enriched subtype.